Zymeworks (ZYME) Stock Price, Quote, News & History | Benzinga

Zymeworks Inc (ZYME) Stock Price, Quote, News & History

ZYMENASDAQ

Trade with Public

Trade with Public

$31.05

At close: Sep 3, 5:00 PM EST

$31.00

-0.05-0.16%

After Hours: 7:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 619.68K

Day Range

- - -

52 Wk Range

13.60 - 31.17

Market Cap

$2.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

74

Short Interest

9.62%

Days to Cover

8.5

Recent Zymeworks Inc. News

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.

Avi Kapoor

MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut $MSTR target, Barclays raised $MDB target, UBS raised $SMTC target.

Avi Kapoor

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

Vandana Singh

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.

Vandana Singh

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading include Zymeworks (NASDAQ: ZYME), Olema Pharmaceuticals (NASDAQ: OLMA), Brand Engagement Network (NASDAQ: BNAI), Aura Biosciences (NASDAQ: AURA), Tevogen Bio Holdings (NASDAQ: TVGN), ArcelorMittal SA (NYSE: MT), Invivyd (NASDAQ: IVVD), ORIC Pharmaceuticals (NASDAQ: ORIC), York Space Systems (NYSE: YSS), and Heartland Express (NASDAQ: HTLD).

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-119.34M

Investing Cash Flow (TTM)

92.77M

Financing Cash Flow (TTM)

107.57M

Free Cash Flow (TTM)

-120.68M

Capital Expenditure (TTM)

-1.35M

Net Change in Cash (TTM)

81.01M

Analyst Trends and Forecast

2

Mar

1

May

2

Jun

1

Jul

6

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.97B

PE Ratio (TTM)

-

PE Ratio (FWD)

23.53

PEG Ratio (TTM)

-

PS Ratio (TTM)

62.51

PB Ratio (TTM)

27.64

Earnings Yield % (TTM)

-6.50%

Earnings Yield % (FWD)

4.25%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.12

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$179.41M

Debt to Equity

0.20

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 619.68K

Day Range

- - -

52 Wk Range

13.60 - 31.17

Market Cap

$2.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

74

Short Interest

9.62%

Days to Cover

8.5

About

Sector

Health Care

Industry

Biotechnology

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Zymeworks (ZYME) stock?

A

You can purchase shares of Zymeworks (NASDAQ:ZYME) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Zymeworks (ZYME) competitors?

A

Other companies in Zymeworks’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Zymeworks (ZYME) stock?

A

Zymeworks has a consensus price target of $38.54.

Q

What is the current price for Zymeworks (ZYME)?

A

The stock price for Zymeworks (NASDAQ: ZYME) is $31 last updated September 2, 2026 at 7:00 PM EDT.

Q

Does Zymeworks (ZYME) pay a dividend?

A

There are no upcoming dividends for Zymeworks.

Q

When is Zymeworks (NASDAQ:ZYME) reporting earnings?

A

Zymeworks does not have any upcoming earnings scheduled.

Q

Is Zymeworks (ZYME) going to split?

A

There is no upcoming split for Zymeworks.

Q

What sector and industry does Zymeworks (ZYME) operate in?

A

Zymeworks is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.